Spots Global Cancer Trial Database for Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Official Title: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Study ID: NCT02810743
Conditions
Study Description
Brief Summary: Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institut Paoli Calmettes, Marseille, , France
Hopital Tenon, University Marie-Curie, Paris, , France
Medical spectrum Twente, Enschede, Overijssel, Netherlands
Antoni van Leeuwenhoek, Amsterdam, , Netherlands
AZVU, Amsterdam, , Netherlands
University Medical Center Groningen, Groningen, , Netherlands
LUMC, Leiden, , Netherlands
Maastricht University Medical Center, Maastricht, , Netherlands
Radboud UMC, NIjmegen, , Netherlands
Erasmus Medical Center Cancer Institute, Rotterdam, , Netherlands
University Medical Center Utrecht, Utrecht, , Netherlands
Contact Details
Name: Sabine Linn, Prof. MD
Affiliation: NKI-AvL
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
